CRISPR-Cpf1, an alternative to Cas9 for targeting AT-rich genomes

Did you know that use of CRISPR endonuclease Cpf1 (also known as Cas12a) can greatly expand the number of target sites available for genome editing? Unlike the G-rich PAM requirement of Cas9, Cpf1 recognizes a T-rich PAM, TTTV. Not only is this enzyme useful for targeting AT-rich genomes, but it has applications in altering disease or phenotype-linked mutations in AT-rich regions through homology-directed repair. In addition, Cpf1 does not require a tracrRNA for function. Learn more about Cpf1 editing efficiency and TTTV site frequency in this article.

Read More>